Metastatic 'switch' could lead to cancer therapies

September 11, 2012 by Anne Ju in Cancer

(Medical Xpress)—What kills cancer patients often isn't the primary tumor; it's when the tumor metastasizes—or spreads the cancer to other areas of the body.

Focusing on colorectal cancer, a leading cause of worldwide, a multidisciplinary research team has shed new light on how these metastasize by identifying a key chemical signaling factor that triggers the process.

What's more, they have engineered a low-cost, surgery-free genetic "switch" that turns metastatic behavior of colorectal cancer cells on and off, allowing for easy, repeatable study of this process.

The research is detailed in the , published Sept. 4, and was led by Huanhuan Joyce Chen, a graduate student under Xiling Shen, assistant professor of electrical and computer engineering and a field member of biomedical engineering. Shen is a co-author with Steven Lipkin, associate professor of medicine at Weill Cornell Medical College. The work was also highlighted online by the company Qiagen.

The researchers found that particular signaling mechanisms called chemokines induce metastasis of colorectal cancer cells. Chemokines are "motility factors" because they help cells move throughout the body. They are known, for example, to be important in the body's immunoresponse, which requires to travel quickly to areas of inflammation or infection.

The researchers established a link between a particular chemokine receptor, called CCR9, and its chemokine CCL25, to the metastatic behavior of colorectal cancer cells. Normal expression of these chemokines keeps the cancer cells in the gut, but once the cells lose CCR9 expression, they can spread. In other words, cancer cells hijack the signaling mechanism.

This discovery in itself, Shen said, could form the basis for targeted anti-metastatic therapies.

A barrier to , however, is the lack of good animal models to test therapies, Shen said, and human clinical trials often fail as a result.

So Chen used her engineering background to take things a step further: She made a mouse with a CCL25 and CCR-9 metastatic "switch" that could be turned on and off after cancer cells were injected into the mouse. At first, the cells expressed the CCR9 receptor, and the tumor only formed in the gut. Turning off the switch made the cells lose the signaling mechanism, and metastasis occurred.

This switch could eliminate the traditional way scientists study metastasis: expensive, low-throughput surgical implantation of metastasized cancer cells. With the switch, metastasis can be studied and repeated by a simple injection of colorectal cancer cells.

Journal reference: Journal of Clinical Investigation search and more info website

Provided by Cornell University search and more info website

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

Key find for early bladder cancer treatment

Aggressive forms of bladder cancer involve the protein PODXL – a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.

Cancer created 47 minutes ago | popularity 5 / 5 (1) | comments 0

Cold plasma successful against brain cancer cells

For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized ...

Cancer created 1 hour ago | popularity 5 / 5 (1) | comments 0 | with audio podcast

Non-Hodgkin lymphoma survival doubles since early 1970s

More than half of patients diagnosed with Non-Hodgkin Lymphoma (NHL) are now surviving the disease thanks to improved diagnosis and treatment, according to a new report1 from Cancer Research UK.

Cancer created 1 hour ago | popularity 5 / 5 (1) | comments 0

Researchers find possible 'master switch' in deadly brain cancer

(Medical Xpress)—Researchers at the University of Virginia School of Medicine have identified a promising target for treating glioblastoma, one that appears to avoid many of the obstacles that typically frustrate efforts ...

Cancer created 2 hours ago | popularity 3.5 / 5 (2) | comments 0 | with audio podcast

American cancer society celebrates 100 years of progress

(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.

Cancer created 16 hours ago | popularity not rated yet | comments 0


Study reveals active site of enzyme linked to stuttering

(Medical Xpress)—Scientists from the Joint Center for Structural Genomics (JCSG) at SLAC National Accelerator Laboratory have determined the 3-D structure of the chemically active part of an enzyme involved ...

Are kids who take music lessons different from other kids?

(Medical Xpress)—Research by U of T Mississauga psychology professor Glenn Schellenberg reveals that two key personality traits – openness-to-experience and conscientiousness—predict better than IQ ...

New discovery in fight against deadly meningococcal disease

Professor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, was part of an international team that discovered the previously unknown pathway of how the bacterium colonizes people.

Pay attention: How we focus and concentrate

Scientists at Newcastle University have shed new light on how the brain tunes in to relevant information.

Parents can help preteens with abduction concerns

Parents naturally are concerned for their children's safety, particularly when there is news of a child abduction that happens close to home. Finding the balance between emotions and the "teachable moment" as parents talk ...

New imaging techniques used to help patients suffering from epilepsy

New techniques in imaging of brain activity developed by Jean Gotman, from McGill University's Montreal Neurological Institute, and his colleagues lead to improved treatment of patients suffering from epilepsy. The combination ...